- Evommune's lead drug fails in chronic hives, stock sinksEvommune's shares {$EVMN} fell more than 30% on Monday morning after the biotech reported its first major trial readout since going public last year. In chronic spontaneous urticaria, a skin cond…Endpoints · 27d ago↗ source
- Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in bone diseasePlus news about Alebund Pharmaceuticals, Regenxbio and Neuphoria Therapeutics. 💸 A SPAC!: Talawar Therapeutics will land on the Nasdaq via a combination with blank-check company JATT II Acquisit…Endpoints · 27d ago↗ source
- Post-Hoc: China deals are pharma’s new tax inversionsAbout a decade ago, when I had just started covering pharma, one of the biggest stories was tax inversions. For those who don’t remember, tax inversions were a form of M&A in which a US ...